Differential Cell Count and CRP Level in Blood as Predictors for Middle East Respiratory Syndrome Coronavirus Infection in Acute Febrile Patients during Nosocomial Outbreak

Ga Eun Park, Cheol-In Kang, Jae-Hoon Ko, Sun Young Cho, Young Eun Ha, Yae-Jean Kim, Kyong Ran Peck, Jae-Hoon Song, and Doo Ryeon Chung

A case-control study was performed to identify clinical predictors for Middle East respiratory syndrome coronavirus (MERS-CoV) infection among patients with acute febrile illness during the nosocomial outbreak. Patients with MERS-CoV were more likely to have monocytosis with normal white blood cell (WBC) count and lower C-reactive protein (CRP) level. Simple laboratory data such as complete blood counts (CBC) with differential count could be a useful marker for the prediction of MERS and triage at the initial presentation of acute febrile patients in outbreak setting.

Keywords: Middle East Respiratory Syndrome; Coronavirus; Predictors; Monocytosis

The Republic of Korea experienced the largest outbreak of Middle East respiratory syndrome coronavirus (MERS-CoV) infection outside the Arabian Peninsula in 2015, including 186 laboratory-confirmed cases (1,2). The reported data suggest that MERS-CoV is most likely to be transmitted as healthcare-associated infections and poses a serious risk for nosocomial outbreak (1-6). During the nosocomial outbreak of MERS, many patients were identified and quarantined by means of active surveillance. Since MERS-CoV is still a fairly new disease, there is a paucity of data regarding the characteristics of and differences between suspected patients whose tests were subsequently negative and laboratory-confirmed cases (7). Even though potential predictors of MERS-CoV infection among patients with community-acquired pneumonia (CAP) were identified in the previous study performed in Saudi Arabia (7), information on possible predictors of infection during the nosocomial outbreak of MERS is still lacking. Therefore, we performed this study to identify possible clinical predictors which can differentiate MERS-CoV-positive patients from MERS-CoV-negative patients with acute febrile illness during the nosocomial outbreak.

We performed a case-control study to identify potential clinical predictors and evaluate differences of initial laboratory data including complete blood counts (CBC) with differential count as predictors for MERS-CoV infection. The cases were defined as hospitalized patients with laboratory-confirmed MERS-CoV infection in the Samsung Medical Center (SMC), a 1,950-bed university-affiliated tertiary care center, between May 2015 and July 2015. The controls were selected from the pool of patients, mostly healthcare workers, who were admitted to the SMC with acute febrile illness (body temperature > 38°C) suspected of viral infection during the same period of the outbreak. The confirmatory diagnostic testing for patients suspected to have MERS-CoV infection was performed as reported previously (8), and the controls were classified when the MERS-CoV test was negative. Patients were excluded if they did not have epidemiologic links with the nosocomial outbreak in the SMC, or if initial blood tests were not done in the SMC. Patients who were transferred from other hospitals and those who had serious underlying diseases such as solid cancer, hematologic malignancy, life-threatening uncontrolled infections, congestive heart failure or acute myocardial infarction were also excluded in the study population (Fig. 1). We obtained the following data for each patient from electronic medical records; age, gender, clinical symptoms, underlying diseases, and initial laboratory findings including CBC with differential count, total bilirubin, alanine aminotrans-
45 patients with MERS admitted in the hospital were screened
2 patients not associated with the Samsung Medical Center were excluded
1 patient who had not done initial lab testing in the hospital was excluded
1 patient hospitalized in the other hospital when MERS had been confirmed was excluded
11 patients were excluded who had serious underlying disease such as
- Solid cancer (n = 5)
- Hematologic malignancy (n = 4)
- Life threatening uncontrolled infection (n = 1)
- Congestive heart failure or myocardial infarction (n = 1)

30 patients with MERS were included

Fig. 1. Study inclusion and exclusion criteria applied for patient identification.
MERS = Middle East respiratory syndrome.

Table 1. Comparison of clinical characteristics and laboratory findings on the admission

| Variables                         | Case group (n = 30) | Control group (n = 43) | P value |
|-----------------------------------|--------------------|------------------------|--------|
| Age, yr (mean ± SD)               | 43.77 ± 14.48      | 32.47 ± 8.85           | < 0.001|
| Male                              | 18 (60.0)          | 13 (28.3)              | 0.006  |
| Symptoms                          |                    |                        |        |
| Fever                             | 26 (86.7)          | 43 (100.0)             | 0.025  |
| Myalgia                           | 15 (50.0)          | 31 (71.2)              | 0.054  |
| Headache                          | 9 (30.0)           | 8 (18.6)               | 0.257  |
| Respiratory symptoms*             | 11 (36.7)          | 5 (11.6)               | 0.011  |
| Diarrhea                          | 2 (6.7)            | 24 (55.8)              | < 0.001|
| Sore throat                       | 4 (13.3)           | 10 (23.3)              | 0.289  |
| Underlying disease                |                    |                        |        |
| Cardiovascular disease†           | 4 (13.3)           | 0 (0.0)                | 0.025  |
| Pulmonary disease                 | 0 (0.0)            | 0 (0.0)                |        |
| Liver disease                     | 0 (0.0)            | 1 (2.4)                | 1.000  |
| Renal disease                     | 0 (0.0)            | 0 (0.0)                |        |
| Neurologic disease§               | 2 (6.7)            | 0 (0.0)                | 0.166  |
| DM                                | 3 (10.0)           | 0 (0.0)                | 0.065  |
| HTN                               | 5 (16.7)           | 0 (0.0)                | 0.009  |
| Laboratory tests                  |                    |                        |        |
| Leukocytosis*                     | 0 (0.0)            | 21 (48.8)              | < 0.001|
| WBC, /mm³ (median, IQR)           | 4,700 (4,010–5,582)| 10,010 (7,890–12,750) | -      |
| Lymphopenia†                      | 9 (30.0)           | 43 (100.0)             | < 0.001|
| ALC, /mm³ (median, IQR)           | 1,170 (776–1,489)  | 877 (608–1,378)        | -      |
| Monocytosis**                     | 20 (66.7)          | 10 (23.3)              | < 0.001|
| Monocyte, % (median, IQR)         | 12.1 (7.78–15.23)  | 5.4 (4.0–7.2)          | < 0.001|
| Anemia (Hb < 13.6 g/dL)           | 10 (33.3)          | 24 (55.8)              | 0.058  |
| Thrombocytopenia (Platelet < 141 × 10³/μL) | 4 (13.3)          | 2 (4.7)                | 0.185  |
| Hyperbilirubinemia (1.5 mg/dL > Total bilirubin) | 0 (0.0)           | 2 (4.7)                | 0.509  |
| Elevated AST (> 40 U/L)           | 8 (26.7)           | 3 (7.0)                | 0.021  |
| Elevated ALT (> 40 U/L)           | 6 (20.0)           | 2 (4.7)                | 0.058  |
| Low CRP ( < 0.5 mg/dL)            | 11 (36.7)          | 2 (4.7)                | < 0.001|
| CRP, mg/dL (median, IQR)          | 0.76 (0.18–1.78)   | 1.82 (1.16–4.43)       | < 0.001|

Data are expressed as the number (%) of patients, unless indicated otherwise.
SD = standard deviation, DM = diabetes mellitus, HTN = hypertension, IQR = interquartile range, WBC = white blood cell, ALC = absolute lymphocyte count, Hb = hemoglobin, AST = aspartate aminotransferase, ALT = alanine aminotransferase, CRP = C-reactive protein, ANC = absolute neutrophil count.
*Newly developed cough, sputum, dyspnea; †Stable angina, well controlled arrhythmia; ‡Chronic hepatitis B; §History of transient ischemic attack without neurologic sequelae; †A total WBC above 11,000/mm³ along with an ANC; ‡The percent lymphocytes on the WBC differential lower than 20%; **The percent monocytes on the WBC differential more than 8%.
The clinical presentations associated with MERS-CoV infection ranged from mild to fulminant, similar to severe acute respiratory syndrome (SARS) (9-11). The initial symptoms in the most MERS cases were nonspecific fever, usually accompanied by cough, sore throat, myalgia, headache, and diarrhea. However, these symptoms are also common in other viral infections (1,3,5,7,8). Common laboratory findings of MERS were also similar to those of SARS and other respiratory viral infections, and lymphopenia was observed generally among MERS patients (3,4,8,12). A recent study noted that MERS-confirmed patients were more likely to have normal WBC count than patients with CAP other than MERS-CoV infection (7). However, these findings may not be applicable to discriminate MERS from acute febrile illness other than MERS because only patients with CAP were included in the previous study (7). Furthermore, there were few reports regarding specific laboratory features as predictors for MERS-CoV infection in acute febrile patients without pneumonia during the nosocomial outbreak. Several studies reported that initial laboratory results including normal WBC with lymphopenia and thrombocytopenia were common among SARS patients (10,11,13,14). These laboratory features allowed early classification of febrile patients into likely and unlikely SARS group to utilize limited isolation facilities effectively (9-11,13,14).

Simple clinical markers of host inflammatory responses may be WBC count with differential and CRP. These variables, even if often non-specific, give important information to the clinician and help to decide diagnosis and treatment strategy (12). The current study suggests that acute febrile patients with recent contact history of MERS, travel history to Middle East, or working history at a hospital affected by MERS could be screened for the possibility of MERS by means of initial laboratory features (e.g. monocytois with normal WBC count). Initial CRP level was significantly lower in the case patients with MERS-CoV infection than in the control group without MERS, at least in the initial presentation, and it can be also helpful to predict the possibility of MERS-CoV infection.

Our study has several limitations. First, clinical and laboratory data were retrospectively collected through electronic medical records, and thus unknown risk factors and bias might have been unequally distributed between the two groups, although cases were enrolled prospectively by means of active surveillance of outbreaks. Second, our findings are not generalizable to immunocompromised patient and those with pneumonia, because most patients in this study were immunocompetent hosts without pneumonia. Finally, these laboratory findings suggested in our study are not the definite diagnostic method for MERS-CoV, and it may only be the adjunctive tool for quarantine strategy during the MERS hospital outbreak. Despite these shortcomings, we believe that our study provides clinically useful findings for infection control strategy, especially in the MERS hospital outbreak.
nosocomial outbreak setting.

In conclusion, our study suggests that initial laboratory findings of patients with acute febrile illness could be potential predictors for MERS-CoV infection during the nosocomial outbreak. Monocytosis with normal WBC count and low CRP level may be useful markers for the prediction of MERS and triage at the initial presentation of acute febrile patients.

ACKNOWLEDGMENT

All authors would like to express our sincere consolation for the patients and their family who had suffered from MERS-CoV infection. We also greatly appreciate the efforts of the health care workers and their families in Samsung Medical Center, who worked tirelessly during this outbreak.

DISCLOSURE

The authors have no potential conflicts of interest to disclose.

AUTHOR CONTRIBUTION

Research conception and design: Park GE, Kang CI. Performing the experiments: Park GE, Kang CI, Ko JH, Cho SY, Ha YE, Kim YG, Peck KR, Song JH, Chung DR. Data acquisition: Park GE, Kang CI. Data analysis and interpretation: Park GE, Kang CI. Statistical analysis: Park GE. Drafting of the manuscript: Park GE, Kang CI. Critical revision of the manuscript: Park GE, Kang CI. Approval of final manuscript: all authors.

ORCID

Ga Eun Park http://orcid.org/0000-0001-7297-2683
Cheol-In Kang http://orcid.org/0000-0002-1741-4459
Jae-Hoon Ko http://orcid.org/0000-0002-9490-6609
Sun Young Cho http://orcid.org/0000-0001-9307-2369
Young Eun Ha http://orcid.org/0000-0001-5213-7082
Yae-Jean Kim http://orcid.org/0000-0002-8367-3424
Kyong Ran Peck http://orcid.org/0000-0002-7464-9780
Jae-Hoon Song http://orcid.org/0000-0001-5419-9789
Doo Ryeon Chung http://orcid.org/0000-0001-9267-101X

REFERENCES

1. Korea Centers for Disease Control and Prevention. Middle East respiratory syndrome coronavirus outbreak in the Republic of Korea, 2015. Osong Public Health Res Perspect 2015; 6: 269-78.
2. Korean Society of Infectious Diseases; Korean Society for Healthcare-associated Infection Control and Prevention. An unexpected outbreak of Middle East respiratory syndrome coronavirus infection in the Republic of Korea, 2015. Infect Chemother 2015; 47: 120-2.
3. Al-Abdallatif MM, Payne DC, Alqasrawi S, Rha B, Tohme RA, Abedi GR, Al Nsour M, Iblan I, Jarour N, Farag NH, et al. Hospital-associated outbreak of Middle East respiratory syndrome coronavirus: a serologic, epidemiologic, and clinical description. Clin Infect Dis 2014; 59: 1225-33.
4. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, Flemhan B, Al-Nassir WN, Balkhy HH, Al-Hakeem RF, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 2013; 13: 752-61.
5. Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, Cummings DA, AlAbdullatif ZN, Assad M, Almulhim A, Makhdoom H, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 2013; 369: 407-16.
6. Oh MD, Choe PG, Oh HS, Park WB, Lee SM, Park J, Lee SK, Song JS, Kim NJ. Middle East respiratory syndrome coronavirus superspreading event involving 81 persons, Korea 2015. J Korean Med Sci 2015; 30: 1701-5.
7. Al-Tawfiq JA, Hinedi K, Ghandour J, Khairalla H, Musleh S, Ujayli A, Mehmish ZA. Middle East respiratory syndrome coronavirus: a case-control study of hospitalized patients. Clin Infect Dis 2014; 59: 160-5.
8. Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet 2013; 386: 995-1007.
9. Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, Ahuja A, Yung MY, Leung CB, To KF, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348: 1986-94.
10. Liu CY, Huang LJ, Lai CH, Chen HP, Chen TL, Fung CP, Liu CY. Clinical characteristics, management and prognostic factors in patients with probable severe acute respiratory syndrome (SARS) in a SARS center in Taiwan. J Chin Med Assoc 2005; 68: 110-7.
11. Tsang KW, Ho PL, Ooi GC, Yee WK, Wong T, Chan-Yeung M, Lam WK, Seto WH, Yam LY, Cheung TM, et al. A cluster of cases of severe acute respiratory infection in Hong Kong. N Engl J Med 2003; 348: 1977-85.
12. McClain MT, Park LP, Nicholson B, Veldman T, Zaas AK, Turner R, Lambkin-Williams R, Gilbert AS, Ginsburg GS, Woods CW. Longitudinal analysis of leukocyte differentials in peripheral blood of patients with acute respiratory viral infections. J Clin Virol 2013; 58: 689-95.
13. Chng WJ, Lai HC, Earnest A, Kuperan P. Haematological parameters in severe acute respiratory syndrome. Clin Lab Haematol 2005; 27: 15-20.
14. Wong RS, Wu A, To KE, Lee N, Lam CW, Wong CK, Chan PK, Ng MH, Yu LM, Hui DS, et al. Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis. BMJ 2003; 326: 1358-62.